Astrantus’s Editas Medicine EDIT Stock Holding History

Astrantus’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,189	Closed	-$456K	–	212
2021 Q4	$456K	Buy	+17,189	New	+$592K	0.34%	121

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Astrantus's EDIT Position: Q1 2022 in Review

Astrantus sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 17,189 shares — an estimated $456K sold.

Astrantus first reported a position in EDIT in Q4 2021 and held it in 1 quarter. The position peaked at $456K in Q4 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Astrantus reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
Astrantus sold 17,189 Editas Medicine shares in Q1 2022, an estimated $456K.
Astrantus first reported a position in Editas Medicine in Q4 2021 and held it in 1 quarter.
Astrantus's Editas Medicine position peaked at $456K in Q4 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.